Table 5.

Gliptin accountability scores for suggestive-or-compatible MMP-induction patients.

Challenge	1st gliptin dose to MMP onset (wk)	Challengea	Dechallenge		Rechallenge R0/R+/R–	Begaud’s accountability scoresb			Naranjo’s scorec
gliptin patient			Yes/no	Outcome		C1–C3	S1–S3	I1–16	0–13	ADR
Dechallenge
Saxagliptin
1	4	Suggestive	Yes	Suggestive	R0	C3	S1	I4	3	Possible
Vildagliptin
2	4	Suggestive	Yes	Suggestive	R0	C3	S1	I4	3	Possible
3	4	Suggestive	Yes	Inconclusive	R0	C2	S1	I2	2	Possible
4	12	Suggestive	Yes	Inconclusive	R0	C2	S1	I2	2	Possible
5	36	Compatible	Yes	Suggestive	R0	C2	S1	I2	3	Possible
6	36	Compatible	Yes	Not suggestive	R0	C1	S1	I1	2	Possible
7	144	Compatible	Yes	Inconclusive	R0	C1	S2	I2	2	Possible
Sitagliptin
8	104	Compatible	Yes	Suggestive	R+	C3	S1	I4	6	Probable
9	136	Compatible	Yes	Suggestive	R0	C2	S1	I2	3	Possible
10	144	Compatible	Yes	Inconclusive	R0	C1	S1	I1	2	Possible
11	232	Compatible	Yes	Suggestive	R0	C2	S2	I3	3	Possible
No dechallenge
Vildagliptin
12	72	Compatible	No	Suggestive	R0	C2	S1	I2	2	Possible
13	148	Compatible	No	Inconclusive	R0	C1	S1	I1	2	Possible
14	236	Compatible	No	Inconclusive	R0	C1	S2	I2	2	Possible
15	244	Compatible	No	Not suggestive	R0	C1	S2	I2	2	Possible
16	588	Compatible	No	Not suggestive	R0	C1	S1	I1	2	Possible
Sitagliptin
17	144	Compatible	No	Inconclusive	R0	C2	S2	I3	2	Possible

MMP, mucous membrane pemphigoid; wk, week; R0, no rechallenge; R⁺, positive rechallenge; R^–, negative rechallenge; ADR, adverse drug reaction.

^aSuggestive, time to onset ≤12 weeks; compatible, time to onset >12 weeks.

^bChronological score: C1, doubtful; C2, plausible; C3, likely. Symptomatological scoring: S1, doubtful; S2, plausible; S3, likely. Intrinsic accountability scoring [combining chronological (C) and symptomatological (S) scores]: I1 (C1S1), I2 (C1S2 or C2S1), I3 (C2S2), I4 (C1S3 or C3S1), I5 (C2S3 or C3S2), and I6 (C3S3) (32).

^cNarango’s score: >9, definite ADR; 5–8, probable ADR; 1–4, possible ADR; 0, doubtful ADR (34).